Keith Stewart

3.3k total citations
81 papers, 1.2k citations indexed

About

Keith Stewart is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Keith Stewart has authored 81 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 36 papers in Molecular Biology and 28 papers in Oncology. Recurrent topics in Keith Stewart's work include Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (20 papers) and Cancer Treatment and Pharmacology (12 papers). Keith Stewart is often cited by papers focused on Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (20 papers) and Cancer Treatment and Pharmacology (12 papers). Keith Stewart collaborates with scholars based in United States, Canada and Singapore. Keith Stewart's co-authors include Karla Kerlikowske, Henry Sánchez, F. Waldman, Karen Chew, Annette M. Molinaro, Britt‐Marie Ljung, Hal K. Berman, Thea D. Tlsty, James L. Bennington and Clifford R. Jack and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Keith Stewart

76 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith Stewart United States 15 519 447 414 211 150 81 1.2k
Natália Becker Germany 23 851 1.6× 239 0.5× 704 1.7× 388 1.8× 73 0.5× 57 2.0k
Roberta D’Alessandro Italy 22 292 0.6× 65 0.1× 402 1.0× 195 0.9× 114 0.8× 63 1.3k
Francesca Di Stefano Italy 11 423 0.8× 83 0.2× 283 0.7× 45 0.2× 68 0.5× 24 968
Claus G. Haase Germany 14 566 1.1× 78 0.2× 328 0.8× 164 0.8× 61 0.4× 28 1.4k
Amaro Taylor‐Weiner United States 16 659 1.3× 60 0.1× 201 0.5× 323 1.5× 52 0.3× 40 1.4k
David Davidson Canada 18 842 1.6× 44 0.1× 541 1.3× 105 0.5× 103 0.7× 29 2.0k
Thao P. Dang United States 17 656 1.3× 61 0.1× 561 1.4× 243 1.2× 32 0.2× 21 1.4k
Astrid McKeown United Kingdom 12 254 0.5× 71 0.2× 599 1.4× 133 0.6× 54 0.4× 34 1.2k
Rune Smaaland Norway 28 443 0.9× 93 0.2× 908 2.2× 584 2.8× 19 0.1× 69 2.5k
Naim U. Rashid United States 20 1.1k 2.1× 67 0.1× 1.6k 3.8× 792 3.8× 59 0.4× 61 2.6k

Countries citing papers authored by Keith Stewart

Since Specialization
Citations

This map shows the geographic impact of Keith Stewart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Stewart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Stewart more than expected).

Fields of papers citing papers by Keith Stewart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Stewart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Stewart. The network helps show where Keith Stewart may publish in the future.

Co-authorship network of co-authors of Keith Stewart

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Stewart. A scholar is included among the top collaborators of Keith Stewart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Stewart. Keith Stewart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Campos, Cecília Bonolo de, Zhihua Li, Michael St. Paul, et al.. (2025). Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma. Blood. 146(Supplement 1). 3316–3316.
2.
Motamed, Mehras, et al.. (2025). Parkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T‐Cell Therapy. Movement Disorders Clinical Practice. 12(3). 371–374. 1 indexed citations
3.
Devasia, Anup J., Esther Masih‐Khan, Jing Yang, et al.. (2024). Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin. Blood. 144(Supplement 1). 3787–3787. 1 indexed citations
4.
Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2022). Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma. Transplantation and Cellular Therapy. 28(3). S186–S187. 2 indexed citations
5.
6.
Xu, Qinqin, Yue-xian Hou, Paul R. Langlais, et al.. (2016). Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival. BMC Cancer. 16(1). 297–297. 35 indexed citations
7.
Gerrie, Alina S., Joseph Mıkhael, Lu Cheng, et al.. (2013). D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. British Journal of Haematology. 161(6). 802–810. 47 indexed citations
8.
Kumar, Shaji, Martha Q. Lacy, Suzanne R. Hayman, et al.. (2011). Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology. 86(8). 640–645. 44 indexed citations
9.
Kerlikowske, Karla, Annette M. Molinaro, Hal K. Berman, et al.. (2010). Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. JNCI Journal of the National Cancer Institute. 102(9). 627–637. 253 indexed citations
10.
Simpson, Lijo, S. Vincent Rajkumar, Angela Dispenzieri, et al.. (2008). High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma. Journal of Clinical Oncology. 26(15_suppl). 8586–8586. 6 indexed citations
11.
Kumar, Shaji, Suzanne R. Hayman, Francis K. Buadi, et al.. (2007). Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. Blood. 110(11). 190–190. 7 indexed citations
12.
Chang, Hong, Young Trieu, Xiaoying Qi, et al.. (2006). Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Research. 31(6). 779–782. 57 indexed citations
13.
14.
Sébag, Michaël, Keith Stewart, Stephen Palmer, et al.. (2006). A Novel Transgenic Mouse Model of Multiple Myeloma Reliably Predicts Drug Response.. Blood. 108(11). 241–241. 1 indexed citations
15.
Crump, Michael, Jeffrey H. Lipton, David W. Hedley, et al.. (1999). Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 13(3). 343–347. 30 indexed citations
16.
Stewart, Keith, Armand Keating, David Sutton, et al.. (1991). Adult Acute Lymphoblastic Leukaemia: The Value of Therapy Intensification. Leukemia & lymphoma. 4(2). 103–110. 7 indexed citations
17.
Stewart, Keith, Andre C. Schuh, & Armand Keating. (1991). T-Cell Blast Crisis in Chronic Myeloid Leukemia. Leukemia & lymphoma. 3(5-6). 319–324. 3 indexed citations
18.
Stewart, Keith, et al.. (1990). Assessment of anomalous sentences repetition test. Journal of Neurology Neurosurgery & Psychiatry. 53(7). 611–612. 5 indexed citations
19.
Stewart, Keith, K. C. Carstairs, Ian D. Dubé, & Armand Keating. (1990). Neutrophilic myelofibrosis presenting as philadelphia chromosome negative BCR non‐rearranged chronic myeloid leukemia. American Journal of Hematology. 34(1). 59–63. 14 indexed citations
20.
Mamelak, Mortimer, et al.. (1979). Narcolepsy: a family study.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 14(5). 821–34. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natália Becker Breakdown of academic impact, for papers by Roberta D’Alessandro Breakdown of academic impact, for papers by Francesca Di Stefano Breakdown of academic impact, for papers by Claus G. Haase Breakdown of academic impact, for papers by Amaro Taylor‐Weiner Breakdown of academic impact, for papers by David Davidson Breakdown of academic impact, for papers by Thao P. Dang Breakdown of academic impact, for papers by Astrid McKeown Breakdown of academic impact, for papers by Rune Smaaland Breakdown of academic impact, for papers by Naim U. Rashid
Rankless by CCL
2026